Lung transplant study tracks hidden virus breakthroughs

This study follows 40 lung transplant patients who are at high risk for CMV infection because the donor had CMV but the recipient did not. Researchers want to learn how often the virus breaks through during standard antiviral treatment with valganciclovir. They will also track side effects like low white blood cell counts. The goal is to better understand these infections and improve future care.